vs
Side-by-side financial comparison of AbbVie (ABBV) and AbCellera Biologics Inc. (ABCL). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $44.9M, roughly 370.5× AbCellera Biologics Inc.). AbbVie runs the higher net margin — 10.9% vs -19.9%, a 30.9% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 10.0%). AbbVie produced more free cash flow last quarter ($4.9B vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 16.2%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
ABBV vs ABCL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $44.9M |
| Net Profit | $1.8B | $-8.9M |
| Gross Margin | 72.6% | — |
| Operating Margin | 27.3% | -63.7% |
| Net Margin | 10.9% | -19.9% |
| Revenue YoY | 10.0% | 788.4% |
| Net Profit YoY | 8354.5% | 73.9% |
| EPS (diluted) | $1.02 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $44.9M | ||
| Q3 25 | $15.8B | $9.0M | ||
| Q2 25 | $15.4B | $17.1M | ||
| Q1 25 | $13.3B | $4.2M | ||
| Q4 24 | $15.1B | $5.0M | ||
| Q3 24 | $14.5B | $6.5M | ||
| Q2 24 | $14.5B | $7.3M | ||
| Q1 24 | $12.3B | $10.0M |
| Q4 25 | $1.8B | $-8.9M | ||
| Q3 25 | $186.0M | $-57.1M | ||
| Q2 25 | $938.0M | $-34.7M | ||
| Q1 25 | $1.3B | $-45.6M | ||
| Q4 24 | $-22.0M | $-34.2M | ||
| Q3 24 | $1.6B | $-51.1M | ||
| Q2 24 | $1.4B | $-36.9M | ||
| Q1 24 | $1.4B | $-40.6M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | -63.7% | ||
| Q3 25 | 12.1% | -851.8% | ||
| Q2 25 | 31.7% | -290.2% | ||
| Q1 25 | 28.0% | -1479.6% | ||
| Q4 24 | -9.9% | -1441.0% | ||
| Q3 24 | 26.5% | -1439.4% | ||
| Q2 24 | 27.6% | -1276.2% | ||
| Q1 24 | 22.7% | -551.5% |
| Q4 25 | 10.9% | -19.9% | ||
| Q3 25 | 1.2% | -637.8% | ||
| Q2 25 | 6.1% | -203.3% | ||
| Q1 25 | 9.6% | -1077.2% | ||
| Q4 24 | -0.1% | -677.6% | ||
| Q3 24 | 10.8% | -785.4% | ||
| Q2 24 | 9.5% | -504.3% | ||
| Q1 24 | 11.1% | -408.0% |
| Q4 25 | $1.02 | $-0.03 | ||
| Q3 25 | $0.10 | $-0.19 | ||
| Q2 25 | $0.52 | $-0.12 | ||
| Q1 25 | $0.72 | $-0.15 | ||
| Q4 24 | $-0.03 | $-0.11 | ||
| Q3 24 | $0.88 | $-0.17 | ||
| Q2 24 | $0.77 | $-0.13 | ||
| Q1 24 | $0.77 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $128.5M |
| Total DebtLower is stronger | $58.9B | — |
| Stockholders' EquityBook value | $-3.3B | $966.9M |
| Total Assets | $134.0B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $128.5M | ||
| Q3 25 | $5.7B | $83.2M | ||
| Q2 25 | $6.5B | $92.4M | ||
| Q1 25 | $5.2B | $159.3M | ||
| Q4 24 | $5.6B | $156.3M | ||
| Q3 24 | $7.3B | $126.6M | ||
| Q2 24 | $13.2B | $148.3M | ||
| Q1 24 | $18.1B | $123.6M |
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
| Q4 25 | $-3.3B | $966.9M | ||
| Q3 25 | $-2.6B | $964.0M | ||
| Q2 25 | $-183.0M | $1.0B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $3.3B | $1.1B | ||
| Q3 24 | $6.0B | $1.1B | ||
| Q2 24 | $6.8B | $1.1B | ||
| Q1 24 | $8.0B | $1.1B |
| Q4 25 | $134.0B | $1.4B | ||
| Q3 25 | $133.9B | $1.4B | ||
| Q2 25 | $137.2B | $1.4B | ||
| Q1 25 | $136.2B | $1.3B | ||
| Q4 24 | $135.2B | $1.4B | ||
| Q3 24 | $143.4B | $1.4B | ||
| Q2 24 | $141.9B | $1.4B | ||
| Q1 24 | $148.9B | $1.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $-34.7M |
| Free Cash FlowOCF − Capex | $4.9B | $-44.6M |
| FCF MarginFCF / Revenue | 29.4% | -99.4% |
| Capex IntensityCapex / Revenue | 2.0% | 21.9% |
| Cash ConversionOCF / Net Profit | 2.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | $-174.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $-34.7M | ||
| Q3 25 | $7.0B | $-52.6M | ||
| Q2 25 | $5.2B | $-32.4M | ||
| Q1 25 | $1.6B | $-11.6M | ||
| Q4 24 | $7.0B | $-8.0M | ||
| Q3 24 | $5.4B | $-28.9M | ||
| Q2 24 | $2.3B | $-30.0M | ||
| Q1 24 | $4.0B | $-41.7M |
| Q4 25 | $4.9B | $-44.6M | ||
| Q3 25 | $6.6B | $-61.5M | ||
| Q2 25 | $4.9B | $-45.8M | ||
| Q1 25 | $1.4B | $-22.2M | ||
| Q4 24 | $6.8B | $-23.6M | ||
| Q3 24 | $5.2B | $-47.4M | ||
| Q2 24 | $2.0B | $-50.1M | ||
| Q1 24 | $3.8B | $-65.8M |
| Q4 25 | 29.4% | -99.4% | ||
| Q3 25 | 42.1% | -687.0% | ||
| Q2 25 | 31.7% | -267.9% | ||
| Q1 25 | 10.5% | -524.0% | ||
| Q4 24 | 44.7% | -468.0% | ||
| Q3 24 | 35.9% | -728.4% | ||
| Q2 24 | 14.0% | -683.8% | ||
| Q1 24 | 31.3% | -661.5% |
| Q4 25 | 2.0% | 21.9% | ||
| Q3 25 | 2.4% | 99.7% | ||
| Q2 25 | 1.7% | 78.2% | ||
| Q1 25 | 1.8% | 251.1% | ||
| Q4 24 | 1.9% | 309.6% | ||
| Q3 24 | 1.7% | 284.6% | ||
| Q2 24 | 1.7% | 274.6% | ||
| Q1 24 | 1.6% | 242.5% |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
